Skip to main content
Premium Trial:

Request an Annual Quote

Pause Recommended

Two US federal agencies have called for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine so reports of a rare blood clot side effect may be investigated, the Wall Street Journal reports.

"We are recommending a pause in the use of this vaccine out of an abundance of caution," the Food and Drug Administration and the Centers for Disease Control and Prevention say in a joint statement. J&J's SARS-CoV-2 vaccine is a one-dose regimen that received Emergency Use Authorization from the FDA in March and, according to the FDA and CDC, about 6.8 million doses of the vaccine have been administered.

Six women developed cerebral venous sinus thrombosis with low blood platelet levels between six and 13 days after they received the J&J vaccine. The Journal reports that an outside panel is to review the data Wednesday for the CDC, while the FDA will perform its own investigation.

The Verge adds that the European Medicines Agency similarly announced it would be reviewing the J&J vaccine following reports of four cases of blood clots there. The EMA recently reviewed AstraZeneca's SARS-CoV-2 vaccine, which has also been tied to reports of rare blood clots, and the Journal notes that some countries have restricted the administration of the AstraZeneca vaccine to certain age groups.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.